Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity
作者:Colin K. Skepper、Robert J. Moreau、Brent A. Appleton、Bret M. Benton、Joseph E. Drumm、Brian Y. Feng、Mei Geng、Cheng Hu、Cindy Li、Andreas Lingel、Yipin Lu、Mulugeta Mamo、Wosenu Mergo、Mina Mostafavi、Christopher M. Rath、Micah Steffek、Kenneth T. Takeoka、Kyoko Uehara、Lisha Wang、Jun-Rong Wei、Lili Xie、Wenjian Xu、Qiong Zhang、Javier de Vicente
DOI:10.1021/acs.jmedchem.7b01861
日期:2018.4.26
adenylyltransferase inhibitors (PPAT, CoaD). Following several rounds of optimization two promising lead compounds were identified: triazolopyrimidinone 3 and 4-azabenzimidazole 4. Here we disclose our efforts to further optimize these two leads for on-target potency and Gram-negative cellular activity. Enabled by a robust X-ray crystallography system, our structure-based inhibitor design approach delivered
在前面的手稿中[Moreau et al。2018,10.1021 / acs.jmedchem.7b01691]我们描述了一个成功的基于片段的铅发现(FBLD)策略用于细菌磷酸泛酰腺苷酰转移酶抑制剂(PPAT,COAD)的发现。经过几轮优化,确定了两个有前途的先导化合物:三唑并嘧啶酮3和4-氮杂苯并咪唑4。在这里,我们公开了我们的工作,以进一步优化针对靶点效力和革兰氏阴性细胞活性的这两种线索。借助强大的X射线晶体学系统,我们基于结构的抑制剂设计方法可提供具有比其各自片段起始点大4–5个数量级的生化潜能的化合物。通过对细菌渗透性和理化性质的观察指导其他优化,这最终导致鉴定出具有针对野生型大肠杆菌的细胞活性的PPAT抑制剂。